New office to support US-focused product line expansion,
growing customer base, and increasing sales initiatives such as the
upcoming 2015 AACC Annual Meeting
Atlanta, GA, July 20, 2015 /CNW/ - MedMira Inc. (MedMira)
(TSXV: MIR) has incorporated MedMira US Inc., a wholly owned
subsidiary, and opened its first US sales and customer service
office in Atlanta, GA. Located in
Buckhead Tower at 3399 Peachtree
Road NE, MedMira US Inc. supports the Company's US sales team,
growing customer base, and fundamental strategic focus on the US
market. A complement to MedMira's corporate, R&D, and
manufacturing facilities in Halifax, Nova
Scotia, Canada, the new US operation will be headed by Dr.
Kevin Jones, who joined MedMira in
2013 with over 20 years of experience in medical, diagnostics, and
life sciences product sales and marketing.
"Atlanta makes a lot of sense
as the location for our first US office, with easy access to our
home base in Canada as well as
global markets, great logistics and warehousing options, and the
headquarters for the Centers for Diseases Control and Prevention
(CDC), the Food and Drug Administration (FDA), the Carter Center,
Care, International Rescue Center, and other potential
collaborators," said Dr. Kevin
Jones, Senior Director, Global Sales & Marketing,
MedMira Inc. "MedMira's new business is largely focused on
the US, and we are devoting significant resources to expand our
sales, product lines, and customer base here. The submission
of our latest rapid HIV test for FDA approval earlier this year was
just the start of expanded product lines we plan to introduce in
the US market as we work directly or with strategic distribution
partners to bring our RVF technology and rapid tests to
customers."
Dr. Jones continued, "The addition of our US office, a key
strategic milestone, is a natural progression of our US sales and
marketing growth, and the timing of opening the office lines up
nicely with our AACC 2015 customer initiatives."
The office opening comes just ahead of MedMira's participation
in the 2015 AACC Annual Meeting & Clinical Lab Expo, the
world's largest gathering for laboratory medicine, which takes
place this year in Atlanta.
MedMira at AACC – Booth #953
The Company will showcase its Rapid Vertical Flow (RVF)
Technology and multiplex rapid tests at the AACC Clinical Lab Expo
taking place, July 28-30 at the
Georgia World Congress Center, Atlanta,
GA. RVF Technology powers the Revealâ G4 Rapid HIV-1
Antibody Test, which was submitted to the FDA for approval in
April 2015, as well as the Company's
multiplex rapid tests for HIV, hepatitis B and C, and syphilis, and
the Miriad research product line. AACC attendees can see RVF
Technology demos at Booth 953 or learn more about this distinct
technology during the following presentations:
OEM Lecture Series – Learn how MedMira RVF Technology is
powering next generation multiplexed rapid diagnostics for
point-of-care settings.
Dr. Kevin Jones, Senior Director,
Global Sales & Marketing
Tuesday, July 28, 2015, 11:00 am – 11:20
am, OEM Pavilion/Industry Theater 2
Poster #B-250 – "Development of Multiplex Rapid POC Test for
Current, Persistent, and Recurring Syphilis Infections Based on the
simultaneous Detection of Treponemal and non-Treponemal Antibodies
in Human Blood Specimens"
Wednesday, July 29, 2015,
9:30 am in the Point-of-Care Testing
session
About MedMira
MedMira is a leading developer and manufacturer of vertical flow
rapid diagnostics. The Company's tests provide hospitals, labs,
clinics and individuals with instant diagnosis for diseases such as
HIV and hepatitis C in just three easy steps. The Company's tests
are sold under the Reveal, Multiplo™ and Miriad™ brands in global
markets. Based on its patented Rapid Vertical Flow Technology,
MedMira's rapid HIV test is the only one in the world to achieve
regulatory approvals in Canada,
the United States, China and the European Union. MedMira's
corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada and
the Company has a sales and customer service office located in
Atlanta, Georgia, United States. For more information visit
medmira.com. Follow us on Twitter and LinkedIn.
This news release contains forward-looking statements, which
involve risk and uncertainties and reflect the Company's current
expectation regarding future events including statements regarding
possible approval and launch of new products, future growth, and
new business opportunities. Actual events could materially
differ from those projected herein and depend on a number of
factors including, but not limited to, changing market conditions,
successful and timely completion of clinical studies, uncertainties
related to the regulatory approval process, establishment of
corporate alliances and other risks detailed from time to time in
the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE MedMira Inc.